ASCO GU 2018 Prostate Cancer
Viewing 15-34 of 88 articles
ASCO GU 2018: Influence of CHAARTED, STAMPEDE, and LATITUDE eligibility criteria on utilization of abiraterone and docetaxel
ASCO GU 2018: Blood-brain barrier penetration of darolutamide compared with enzalutamide using whole body autoradiography
ASCO GU 2018: Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE)
ASCO GU 2018: Ability of multiparametric MRI to predict prostate tumor heterogeneity on targeted biopsy
ASCO GU 2018: First Interim Analysis Of REASSURE, An Observational Study To Assess The Safety Of Radium-223 In Men With Metastatic Castration-resistant Prostate Cancer
ASCO GU 2018: Abiraterone Acetate in Patients Aged 75 or More with mCRPC in Both Pre-chemotherapy or Post-chemotherapy Settings
ASCO GU 2018: Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.
ASCO GU 2018: Impact of Genomic Risk Scores on Treatment Decisions Following Radical Prostatectomy in a Prospective Medicare Registry
ASCO GU 2018: Adjuvant Enzalutamide (ENZA) for Men with Non-metastatic High-risk Prostate Cancer (HRPCa) After Radical Prostatectomy (RP).
ASCO GU 2018: Daily Versus Weekly Prostate Cancer image-guided Radiotherapy: A Phase 3, Multi-center, Randomized Trial